---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027734"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:39:57.345053+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alector Q4 net loss narrows to $2.1M; latozinemab Phase 3 data expected Q4 2025

## Summary
- Q4 2024 net loss $2.1M ($0.02 loss per share) vs $41.4M loss ($0.49 loss) in Q4 2023, revenue $54.2M vs $15.2M.
- Cash, cash equivalents and investments $413.4M, expected to fund operations through 2026.
- Topline data from pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN anticipated by Q4 2025.
- Enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's expected to complete by mid-2025.
- 2025 guidance: collaboration revenue $5-15M, R&D expense $175-185M, G&A $55-65M.

## SEC filing metadata
- accession: 0000950170-25-027734
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/0000950170-25-027734-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/alec-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027734
- JSON: https://secwatch.observer/filing/0000950170-25-027734.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027734.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.